Mass-Vaccination Sites — An Essential Innovation to Curb the Covid-19 Pandemic

Goralnick, Eric; Kaufmann, Christoph C; Gawande, Atul A.

doi:10.1056/nejmp2102535

Cited by 95 publications

(96 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The social distancing model is the use of large-venue mass-vaccination sites (eg, stadiums, convention centers, etc.) when ensuring social distancing among individuals [ 28 ], which is effective in addressing the logistical issues regarding locations, but it is challenging to monitor the social distancing. Meanwhile, the mobile team model is a model that provides vaccines directly to the people.…”

Section: Optimization Of Cost-effective Service Delivery Modelsmentioning

confidence: 99%

Towards efficacy and sustainability of global, regional and national COVID-19 vaccination programs

Vu¹,

Le²,

Huynh

et al. 2021

J Glob Health

View full text Add to dashboard Cite

Section: Optimization Of Cost-effective Service Delivery Modelsmentioning

confidence: 99%

Towards efficacy and sustainability of global, regional and national COVID-19 vaccination programs

Vu¹,

Le²,

Huynh

et al. 2021

J Glob Health

View full text Add to dashboard Cite

“…There is an urgent need for COVID-19 vaccines and therapeutic agents in low and middleincome countries [19][20][21]. Mass vaccination sites will be an important innovation in the containment of the COVID-19 pandemic, but only if the effectiveness and safety of vaccination are ensured [22,23].…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of COVID-19 vaccine: A protocol of systematic review and meta-analysis

Xue

Deng

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The coronavirus disease 2019 (COVID-19) is one of the most wide-spread and threatening infectious diseases in human history. Experts in the field of medicine and biology are working to develop methods to treat and prevent COVID-19. Currently, COVID-19 is predominantly treated with symptomatic therapy and there is still a lack of effective antiviral therapy. Therefore, the prevention and control of novel coronavirus is primarily focused on vaccine development. Several vaccines have been developed, but their relative efficacy and safety have not been proven. Therefore, the aim of this study is to investigate the efficacy and safety of COVID-19 vaccines.Methods and analysis: The electronic databases we will use to retrieve information include PubMed, The Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Database and Weipu Electronics. The retrieval period is from the establishment of the database to March 2021. All randomized controlled trials in humans vaccinated with COVID-19 were collected, and data were independently selected and extracted according to predesigned inclusion/exclusion criteria. Full-text screening, data extraction and quality assessment were conducted independently by two reviewers. Two additional investigators will conduct report quality, risk of bias, sensitivity analysis and subgroup analysis to ensure the reliability of our study results. The software RevMan 5.3 was used for statistical analysis. Systematic review and meta-analyses will be conducted to evaluate the pooled evidence of efficacy and safety of the COVID-19 vaccines.Result: This study will evaluate the efficacy and safety of the COVID-19 vaccines.Conclusion: The conclusions of this study will provide an evidence-based analysis of the safety and efficacy of COVID-19 vaccines.Systematic review registration: PROSPERO CRD42021242581

show abstract

“…To date there has been little emphasis on the use of mass vaccination hubs to be included in vaccination efforts, although previous pandemic planning exercises found this model to be effective, 12 and mass vaccination sites have been implemented successfully in Australia (during Phase 1a of the COVID-19 vaccine roll-out) and overseas. 19,20 Mass vaccination hubs and GP clinics offer distinct advantages as modes of vaccine delivery. As we have shown, mass vaccination hubs are more robust to increased throughput and staff shortages or absences.…”

Section: Policy Implicationsmentioning

confidence: 99%

Modelling vaccination capacity at mass vaccination hubs and general practice clinics

Hanly

Churches

Fitzgerald

et al. 2021

Preprint

View full text Add to dashboard Cite

COVID-19 population vaccination programs are underway globally. In Australia, the federal government has entered into three agreements for the supply of vaccines, with roll-out beginning for the highest priority groups in February 2021. Expansion of the vaccination program throughout February and March failed to meet government targets and this has been attributed to international supply issues. However, Australia has local capacity to manufacture one million doses of the AstraZeneca vaccine weekly and once fully operational this will greatly increase the national vaccination capacity. Under current plans, these vaccine doses will be distributed primarily through a network of general practices, to be joined in later phases by community pharmacies. It remains unclear whether these small distribution venues have the logistical capacity to administer vaccines at the rate they will become available. To inform this discussion, we applied stochastic queue network models to estimate the capacity of vaccination sites based on assumptions about appointment schedules, service times and available staff numbers. We specified distinct queueing models for two delivery modes: (i) mass vaccination hubs located in hospitals or sports arenas and (ii) smaller clinics situated in general practices or community pharmacies. Based on our assumed service times, the potential daily throughput for an eight hour clinic at a mass vaccination hub ranged from around 500 vaccinations for a relatively small hub to 1,400 vaccinations a day for a relatively large hub. For GP vaccination clinics, the estimated daily throughput ranged from about 100 vaccinations a day for a relatively small practice to almost 300 a day for a relatively large practice. Stress tests showed that for both delivery modes, sites with higher staff numbers were more robust to system pressures, such as increased arrivals or staff absences, and mass vaccination sites were more robust that GP clinics. Our analysis is accompanied by an interactive web-based queue simulation applet, which allows users to explore queue performance under their own assumptions regarding appointments, service times and staff availability. Different vaccine delivery modes offer distinct benefits and may be particularly appealing to specific population segments. A combination of expanded mass vaccination hubs and expanded GP vaccination is likely to achieve mass vaccination faster than either mode alone.

show abstract

Mass-Vaccination Sites — An Essential Innovation to Curb the Covid-19 Pandemic

Cited by 95 publications

References 1 publication

Towards efficacy and sustainability of global, regional and national COVID-19 vaccination programs

Towards efficacy and sustainability of global, regional and national COVID-19 vaccination programs

The efficacy and safety of COVID-19 vaccine: A protocol of systematic review and meta-analysis

Modelling vaccination capacity at mass vaccination hubs and general practice clinics

Contact Info

Product

Resources

About